Clinical Trial Update: A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 study evaluates the safety of multiple dose levels of AGS-16M8F in patients with advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AGS-16M8F

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F | Phase 1 | Status: COMPLETED